103 related articles for article (PubMed ID: 11262212)
1. Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B.
Buti M; Sánchez F; Cotrina M; Jardi R; Rodríguez F; Esteban R; Guardia J
J Infect Dis; 2001 Apr; 183(8):1277-80. PubMed ID: 11262212
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
[TBL] [Abstract][Full Text] [Related]
3. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine.
Gauthier J; Bourne EJ; Lutz MW; Crowther LM; Dienstag JL; Brown NA; Condreay LD
J Infect Dis; 1999 Dec; 180(6):1757-62. PubMed ID: 10558928
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
Yuen MF; Sablon E; Hui CK; Yuan HJ; Decraemer H; Lai CL
Hepatology; 2001 Oct; 34(4 Pt 1):785-91. PubMed ID: 11584376
[TBL] [Abstract][Full Text] [Related]
6. Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha.
van der Eijk AA; Niesters HG; Hansen BE; Heijtink RA; Janssen HL; Schalm SW; de Man RA
J Viral Hepat; 2006 Feb; 13(2):96-103. PubMed ID: 16436127
[TBL] [Abstract][Full Text] [Related]
7. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
[TBL] [Abstract][Full Text] [Related]
8. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.
Kohmoto M; Enomoto M; Tamori A; Habu D; Takeda T; Kawada N; Sakaguchi H; Seki S; Shiomi S; Nishiguchi S
J Med Virol; 2005 Feb; 75(2):235-9. PubMed ID: 15602726
[TBL] [Abstract][Full Text] [Related]
9. A real-time quantitative polymerase chain reaction method for hepatitis B virus in patients with chronic hepatitis B treated with lamivudine.
Ide T; Kumashiro R; Koga Y; Tanaka E; Hino T; Hisamochi A; Murashima S; Ogata K; Tanaka K; Kuwahara R; Sata M
Am J Gastroenterol; 2003 Sep; 98(9):2048-51. PubMed ID: 14499786
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.
Lai CL; Dienstag J; Schiff E; Leung NW; Atkins M; Hunt C; Brown N; Woessner M; Boehme R; Condreay L
Clin Infect Dis; 2003 Mar; 36(6):687-96. PubMed ID: 12627352
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy.
Kim JH; Yu SK; Seo YS; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Lee CH; Byun KS
J Gastroenterol Hepatol; 2007 Aug; 22(8):1220-5. PubMed ID: 17532786
[TBL] [Abstract][Full Text] [Related]
12. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
13. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.
Yao GB; Zhu M; Cui ZY; Wang BE; Yao JL; Zeng MD
J Dig Dis; 2009 May; 10(2):131-7. PubMed ID: 19426396
[TBL] [Abstract][Full Text] [Related]
14. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
[TBL] [Abstract][Full Text] [Related]
15. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
Yao G; Cui Z; Wang B; Yao J; Zeng M
Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930
[TBL] [Abstract][Full Text] [Related]
16. The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B.
Shindo M; Hamada K; Nishioji K; Muramatsu A; Oda Y; Okuno T
J Gastroenterol; 2004; 39(3):260-7. PubMed ID: 15065004
[TBL] [Abstract][Full Text] [Related]
17. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
[TBL] [Abstract][Full Text] [Related]
18. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
Ohishi W; Shirakawa H; Kawakami Y; Kimura S; Kamiyasu M; Tazuma S; Nakanishi T; Chayama K
J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
[TBL] [Abstract][Full Text] [Related]
19. Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B.
Heijtink RA; Kruining J; Honkoop P; Kuhns MC; Hop WC; Osterhaus AD; Schalm SW
J Med Virol; 1997 Nov; 53(3):282-7. PubMed ID: 9365897
[TBL] [Abstract][Full Text] [Related]
20. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
Kazim SN; Chauhan R; Das BC; Sarin SK
J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
